| Trial ID: | L6416 |
| Source ID: | NCT05053828
|
| Associated Drug: |
Antiplatelet Drug
|
| Title: |
Type 2 Diabetes With Antiplatelet Drugs
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes|Antiplatelet Drugs|Myocardial Infarction|Heart Failure
|
| Interventions: |
DRUG: Antiplatelet Drug
|
| Outcome Measures: |
Primary: Measure the prevalence of clopidogrel prescription in patients with T2D in the study population., Quantitative, 1 year|Measure the prevalence of ticagrelor and prasugrel prescription in patients with T2D vs. clopidogrel., Quantitative, 1 year|Calculate MedWise Risk Score (TM) of <10, 11-14, 15-19, 20-30, >30 for T2D patients to examine patient risk for adverse drug events., Quatitative, 1 year |
|
| Sponsor/Collaborators: |
Sponsor: Tabula Rasa HealthCare
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
173464
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2021-09-20
|
| Completion Date: |
2023-01-30
|
| Results First Posted: |
|
| Last Update Posted: |
2023-01-31
|
| Locations: |
Tabula Rasa Healthcare, Orlando, Florida, 32827, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05053828
|
